Drugs / Thymoglobulin
Trials 0
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Comparator or background therapy1 trial | ||||||
| Phase 1/2 | NCT00822770 Background | Jan 2009 → Oct 2012 | disease related to hematopoietic stem cell transplant, leukemia | M.D. Anderson Cancer Center | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Thymoglobulin | “ATG (Thymoglobulin)” NCT00822770 ↗ |
| Known as | ATG | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00822770 ↗ |
| Route | Intravenous | “If your stem cell donor is not someone who is related to you, you will receive antithymocyte globulin (ATG) through the CVC once a day from Day -3 through Day -1.” NCT00822770 ↗ |